论文部分内容阅读
目的探讨利拉鲁肽与西格列汀治疗肥胖2型糖尿病(T2DM)患者的临床疗效。方法选取2014年8月至2016年2月丹东市第一医院收治的肥胖T2DM患者104例为研究对象,按照完全随机法分为观察组和对照组,每组52例。观察组患者在应用二甲双胍治疗的基础上应用利拉鲁肽,对照组在应用二甲双胍治疗的基础上应用西格列汀。治疗结束后比较两组患者的空腹血糖(FPG)、糖化血红蛋白(Hb A1c)、体重指数(BMI)及收缩压(SBP)。结果两组患者治疗后FPG、Hb A1c、BMI及SBP均较治疗前降低,差异均有统计学意义(均P<0.05);观察组患者治疗后的BMI及SBP均低于对照组,差异均有统计学意义(均P<0.05)。结论利拉鲁肽和西格列汀均可以有效控制口服二甲双胍效果不佳的T2DM患者的血糖,但利拉鲁肽可显著降低收缩压及体重指数。
Objective To investigate the clinical efficacy of liraglutide and sitagliptin in the treatment of patients with obese type 2 diabetes mellitus (T2DM). Methods Totally 104 obese T2DM patients admitted to the First Hospital of Dandong from August 2014 to February 2016 were selected as study subjects and divided into observation group and control group according to a completely randomized method, with 52 cases in each group. Patients in the observation group were given liraglutide on the basis of metformin treatment, while those in the control group were given sitagliptin on the basis of metformin treatment. After treatment, fasting blood glucose (FPG), Hb A1c, body mass index (BMI) and systolic blood pressure (SBP) were compared between the two groups. Results The FPG, Hb A1c, BMI and SBP in both groups after treatment were significantly lower than those before treatment (all P <0.05). The BMI and SBP in the observation group were lower than those in the control group There was statistical significance (all P <0.05). Conclusion Both liraglutide and sitagliptin are effective in controlling blood glucose in T2DM patients who are not receiving metformin. However, liraglutide can significantly reduce systolic blood pressure and body mass index.